Bimekizumab Outperforms Risankizumab in Arthritis Trial
Data presented in London show bimekizumab achieved higher response rates than risankizumab for psoriatic arthritis patients.
Updated on Oct. 16, 2026 in Arthritis
At the 2026 EULAR Annual Meeting in London, researchers reported that bimekizumab outperformed risankizumab in treating active psoriatic arthritis. The findings from the BE BOLD trial were presented during the June 3-6, 2026, conference.
Why it matters
The study offers a direct comparison between two potent biologics used for inflammatory joint conditions. Understanding how these therapies perform in head-to-head trials is vital for clinicians selecting optimal treatment paths for patients with psoriatic arthritis.
In the trial of 553 adults, bimekizumab patients received a 160 mg dose every 4 weeks. By week 16, bimekizumab also showed superior PASI 100 skin clearance rates of 53.4% compared to 46.6% for risankizumab.
The players
EULAR
The European Alliance of Associations for Rheumatology is a leading international organization dedicated to the study and treatment of rheumatic diseases.
The details
The BE BOLD trial randomized 553 participants, finding that the bimekizumab arm achieved an ACR50 response of 49.1% at week 16. Researchers noted early treatment separation, with response rates of 19.9% for bimekizumab versus 7.2% for risankizumab recorded as early as week 4.
Timeline
June 3-6, 2026: Trial results were presented at the EULAR Annual Meeting.
Week 4: The study observed the first separation in ACR50 response rates.
Week 16: Primary and secondary end point measurements were recorded for all participants.
Health Landscape
This head-to-head trial follows a pattern set by the EULAR Annual Meeting of prioritizing comparative clinical evidence to refine standard treatment protocols for chronic autoimmune diseases. Such studies are critical for evolving medical science as doctors move toward more targeted biologic interventions.
Patients may discuss these findings with their rheumatologist to better understand if bimekizumab is a viable option for managing psoriatic arthritis symptoms. Clinicians must also account for existing labeling warnings regarding suicidality associated with these therapies when evaluating treatment suitability.
The takeaway
This trial underscores the importance of comparative efficacy data in selecting biologic treatments for psoriatic arthritis. Patients should consult their healthcare providers to weigh these success rates against known safety risks, including suicidality warnings.
Further reading
For more information on the latest research and standard care practices, visit the Arthritis section.
Source note: This article includes information reported by Hcplive.
